Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Mallinckrodt
McKinsey
Baxter
Express Scripts
Moodys

Last Updated: October 17, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR EDARAVONE

See Plans and Pricing

« Back to Dashboard

Clinical Trials for Edaravone

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00153946 Edaravone and Argatroban Stroke Therapy Study for Acute Ischemic Stroke Completed Japan Cardiovascular Research Foundation Phase 4 2004-08-01 Edaravone, a free radical scavenger, is a novel neuroprotective agent, and argatroban is a selective thrombin inhibitor. Both the drugs were approved by the Japanese Government, and have frequently been used for the treatment of acute brain infarction in Japan. The effect of combination therapy of these drugs, however, has not yet been elucidated. This study will test the safety and efficacy of the combination therapy with these agents in patients with acute non-cardioembolic and non-lacunar ischemic stroke.
NCT00153946 Edaravone and Argatroban Stroke Therapy Study for Acute Ischemic Stroke Completed Combination Therapy for Acute Ischemic Stroke Study Group Phase 4 2004-08-01 Edaravone, a free radical scavenger, is a novel neuroprotective agent, and argatroban is a selective thrombin inhibitor. Both the drugs were approved by the Japanese Government, and have frequently been used for the treatment of acute brain infarction in Japan. The effect of combination therapy of these drugs, however, has not yet been elucidated. This study will test the safety and efficacy of the combination therapy with these agents in patients with acute non-cardioembolic and non-lacunar ischemic stroke.
NCT00200356 Edaravone-Sodium Ozagrel Comparative Post-Marketing Study on Acute Ischemic Stroke Completed Mitsubishi Tanabe Pharma Corporation Phase 4 2004-08-01 This study is randomized, Sodium Ozagrel (Thromboxane A2 Synthase Inhibitor) controlled study on acute ischemic stroke. The primary endpoints were the rate of patients with modified Rankin Scale score of 0-1 at 3 months.
NCT00265239 Pilot Study of Edaravone to Treat Acute Myocardial Infarction Completed Japan Heart Foundation Phase 4 2001-04-01 Early reperfusion therapy has improved the clinical outcomes of patients with acute myocardial infarction (AMI), but these benefits are limited in some patients by reperfusion injuries. There is now increasing evidence that reactive oxygen species cause reperfusion injury. This study was designed to examine the effects of edaravone, a novel free radical scavenger, in patients with AMI.
NCT00265239 Pilot Study of Edaravone to Treat Acute Myocardial Infarction Completed Kumamoto University Phase 4 2001-04-01 Early reperfusion therapy has improved the clinical outcomes of patients with acute myocardial infarction (AMI), but these benefits are limited in some patients by reperfusion injuries. There is now increasing evidence that reactive oxygen species cause reperfusion injury. This study was designed to examine the effects of edaravone, a novel free radical scavenger, in patients with AMI.
NCT00330681 Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS) Completed Mitsubishi Tanabe Pharma Corporation Phase 3 2006-05-01 The primary objective of this study is to confirm the efficacy of 60 mg of MCI-186 via intravenous drip once a day in patients with ALS based on the changes in the revised ALS functional rating scale (ALSFRS-R) scores after 24 weeks administration in double-blind, placebo-controlled manner. And in addition, this study will be performed to examine the safety of MCI-186 to ALS patients.
NCT00415519 Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS) Who Met Severity Classification III Completed Mitsubishi Tanabe Pharma Corporation Phase 3 2006-12-01 The primary objective of this study is to evaluate the efficacy of 60mg of MCI-186 via intravenous drip once a day in patients with ALS whose severity is classified as grade III, based on the changes in the revised ALS functional rating scale (ALSFRS-R) scores after 24 weeks administration in double-blind, placebo-controlled manner. And in addition, this study will be performed to examine the safety of MCI-186 to ALS patients who met severity classification III.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Edaravone

Condition Name

Condition Name for Edaravone
Intervention Trials
Healthy 3
Amyotrophic Lateral Sclerosis (ALS) 3
Acute Ischemic Stroke 2
Stroke 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Edaravone
Intervention Trials
Motor Neuron Disease 6
Amyotrophic Lateral Sclerosis 6
Sclerosis 5
Stroke 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Edaravone

Trials by Country

Trials by Country for Edaravone
Location Trials
China 35
Japan 6
Hungary 1
Finland 1
Czechia 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Edaravone
Location Trials
Kansas 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Edaravone

Clinical Trial Phase

Clinical Trial Phase for Edaravone
Clinical Trial Phase Trials
Phase 4 3
Phase 3 4
Phase 2 6
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Edaravone
Clinical Trial Phase Trials
Completed 10
Recruiting 5
Not yet recruiting 3
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Edaravone

Sponsor Name

Sponsor Name for Edaravone
Sponsor Trials
Mitsubishi Tanabe Pharma Corporation 9
Jiangsu Simcere Pharmaceutical Co., Ltd. 2
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 2
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Edaravone
Sponsor Trials
Other 16
Industry 12
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Dow
Mallinckrodt
Harvard Business School
Johnson and Johnson
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.